Any Mountain Expedition Team
The Any Mountain project is dedicated to funding research on the prevention and early detection of ovarian cancer. This research is being conducted by an incredible team of gynecologic oncology leaders from around the country.
We are creating the first international surgical ovarian cancer prevention trial which could revolutionize how women choose to decrease their risk of ovarian cancer. Next up: novel efforts to improve early detection, treatment and prevention.
Any Mountain is expressly committed to ending racism within healthcare and beyond. Research priority will be given to projects addressing intersections of racial justice and ovarian cancer. Ending racism saves lives.
The Any Mountain project is made possible by Let Every Woman Know – Alaska and the Minnesota Ovarian Cancer Alliance.
Let Every Woman Know – Alaska
Let Every Woman Know – Alaska is dedicated to raising awareness, sharing information and saving lives by educating people in the Last Frontier and supporting women living with gynecologic cancers. It’s an Alaska-based non-profit, founded by Dr. Joanie Hope, which provides creative state-wide education, support, advocacy, and arts programs unique to the state’sdiverse communities.
Minnesota Ovarian Cancer Alliance
The Minnesota Ovarian Cancer Alliance (MOCA) is one of our key partners and committed to responsibly managing the funds raised for ovarian cancer research through the Any Mountain project. MOCA is a 501(c)3 non-profit organization dedicated to funding ovarian cancer research, providing support to the women and families affected by ovarian cancer, educating the medical community, and raising awareness of ovarian cancer.
Any Mountain Research Awards
The following research projects were approved for one year of funding by Any Mountain in October 2021 and are currently underway.
TUBA-WISP II Study
Principal Investigator: Karen Lu, MD at MD Anderson, Houston, TX
The TUBA-WISP II Study is a world-wide prevention study in high-risk women with multiple centers in the United States. This trial is designed to determine whether removing the fallopian tubes and delaying ovarian removal by 5 years is effective for reducing hereditary ovarian cancer risk, which would allow women to keep their ovarian function intact for a longer period of time. Women self-select whether they want to undergo a standard removal of ovaries and fallopian tubes in one surgery or a new option to remove only the fallopian tubes and some years later remove the ovaries. Any Mountain funds will be used to finalize data forms, set up the national database, assist sites with IRB submissions and begin patient enrollment. Data from similar studies being done in other countries around the world will be pooled together to determine how safe and effective the new prevention option is for high risk women. Data from this trial could change the standard care for women at high risk of ovarian cancer
Understanding Decision Making for Risk Reducing Surgery
Principal Investigator: Kara Long Roche, MD at Memorial Sloan Kettering, NYC
This study will identify common themes and influential factors in the decision to undergo risk-reducing removal of the tubes and ovaries in young women at high genetic risk of developing ovarian cancer. The researchers will determine sociodemographic, medical, and psychosocial factors that contribute to the decision-making process. Data from this study will help us better counsel women about options for managing an increased risk of ovarian cancer.
Predictor of Completion of Genetic Testing: An Ancillary Analysis of the MAGENTA Study
Principal Investigator: Barbara Norquist, MD at University of Washington, Seattle
THE MAGENTA study was a large trial that evaluated how much genetic counseling was needed to deliver testing for cancer genetic risk to women in their homes. This ancillary analysis of the MAGENTA study will help us better understand why some people start the process, but then do not complete genetic testing at home by interviewing women who did and did not complete the testing process. Results from this study will help us identify concerns and barriers to genetic testing for cancer risk and inform future interventions to bring risk assessment to more people.